<DOC>
	<DOCNO>NCT01053689</DOCNO>
	<brief_summary>The purpose bioequivalence study compare test Glimepiride 1 mg tablet Dr.Reddy 's Laboratories Limited versus reference Amaryl 1 mg tablet Aventis Pharmaceuticals Inc healthy subject , feed condition .</brief_summary>
	<brief_title>Bioequivalence Study Dr.Reddys Laboratories Limited , Glimepiride 1 mg Tablets Healthy Subjects Under Fed Condition</brief_title>
	<detailed_description>The study Single centre , randomize , single-dose , open-label,2-way crossover , bioequivalence study compare test Glimepiride 1 mg tablet Dr.Reddy 's Laboratories Limited versus Amaryl 1 mg tablet Aventis Pharmaceuticals Inc healthy subject , feed condition .</detailed_description>
	<mesh_term>Glimepiride</mesh_term>
	<criteria>Male nonchildbearing potential female , smoker nonsmoker,18 year age old . Capable consent . Nonchildbearing potential female subject : Postmenopausal state : absence menses 12 month prior drug . administration hysterectomy bilateral oophorectomy least 6 month prior drug administration . Surgically sterile : hysterectomy , bilateral oophorectomy , tubal ligation least 6 month prior drug administration . Subjects follow applies exclude study : Clinically significant illness &amp; surgery within 4 week prior administration study medication . Any clinically significant abnormality find medical screening . Any reason , opinion Medical SubInvestigator , would prevent subject participate study . Abnormal laboratory test judge clinically significant . Positive test hepatitis B C HIV screen . ECG abnormality ( clinically significant ) vital sign abnormality ( systolic blood pressure low 90 140 mmHg , diastolic blood pressure low 50 90 mmHg , heart rate less 50 100 bpm ) screening . BMIâ‰¥30.0 . History significant alcohol abuse within six month prior screen visit indication regular use fourteen unit alcohol per week ( l Unit=150 mL wine , 360 mL beer , 45 mL 40 % alcohol ) . History drug abuse use illegal drug : use soft drug ( marijuana ) within 3 month prior screen visit hard drug ( cocaine , phencyclidine [ PCP ] crack ) within 1 year prior screen visit positive urine drug screen screen . History allergic reaction glimepiride sulfonylurea ( e.g . chlopropamide , gliclazide , tolbutamide glyburide ) . History allergic reaction heparin . Use drug know induce inhibit hepatic drug metabolism ( examples inducer : barbiturate , carbamazepine , phenytoin , glucocorticoid , rifampinlrifabutin ; examples inhibitor : antidepressant , cimetidine . diltiazem , erythromycin , ketoconazole , MAO inhibitor , neuroleptic , verapamil , quinidine ) within 30 day prior administration study medication . Use investigational drug participation investigational study within 30 day prior administration study medication . . Clinically significant history presence clinically significant gastrointestinal pathology ( e.g . chronic diarrhea . inflammatory bowel disease ) , unresolved gastrointestinal symptom ( e.g . diarrhea , vomit ) , liver kidney disease , condition know interfere absorption , distribution , metabolism . excretion drug . Any clinically significant history presence clinically significant neurological , endocrinal , cardiovascular , pulmonary , hematologic , immunologic , psychiatric , metabolic disease . Use prescription medication ( include hormone therapy ) within 14 day prior administration study medication overthecounter product ( include natural food supplement , vitamin , garlic supplement ) within 7 day prior administration study medication , except topical product without systemic absorption . Difficulty swallow study medication . Smoking 25 cigarette per day . Any food allergy , intolerance , restriction special diet could , opinion Medical SubInvestigator . contraindicate subject 's participation study . A depot injection implant drug within 3 month prior administration study medication . Donation plasma ( 500 mL ) within 7 day prior drug administration . Donation loss whole blood prior administration study medication follow : 50 mL 300 mL whole blood within 30 day , 301 mL 500 mL whole blood within 45 day , 500 mL whole blood within 56 day prior drug administration . Subjects diabetes ( include diabetes mellitus ) . Subjects know serious hepatic impairment . Subjects clinically significant presence history hypoglycemia . Additional exclusion criterion female : Breastfeeding subject . Positive urine pregnancy test screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>Bioequivalence , Glimepiride , Crossover</keyword>
</DOC>